InvestorWire NewsRoom

Article

Brain Scientific (BRSF) Developing State-of-the-Art AI Diagnostic Analytics
March 4, 2021

Brain Scientific (BRSF) Developing State-of-the-Art AI Diagnostic Analytics

  • BRSF working to improve diagnostics by leveraging AI and machine learning
  • Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
  • Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.

But BRSF isn’t stopping there.

The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.

The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase. 

BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://ibn.fm/3V7Wx).

As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://ibn.fm/7pKza). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.

But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.

An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://ibn.fm/s5MWM). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”

Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.

To learn more about this company, visit www.BrainScientific.com/Invest-Now

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up NetworkNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).